These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12647710)

  • 21. Continuation rates and satisfaction with the Levonorgestrel Intrauterine System. Letter to the Editor in response to an article published in volume 31, by Dr. Ewies.
    Rybowski S; Inki P
    Gynecol Endocrinol; 2011 May; 27(5):368-9. PubMed ID: 21463232
    [No Abstract]   [Full Text] [Related]  

  • 22. Levonorgestrel-releasing intrauterine system and new-onset acne.
    Ilse JR; Greenberg HL; Bennett DD
    Cutis; 2008 Aug; 82(2):158. PubMed ID: 18792549
    [No Abstract]   [Full Text] [Related]  

  • 23. [Connection between levonorgestrel-IUD and GAS (Group A Streptococcus) sepsis? Reliable risk assessment is not yet possible].
    Milsom I; Landgren BM; Alestig K
    Lakartidningen; 1995 Dec; 92(50):4781-2. PubMed ID: 8538290
    [No Abstract]   [Full Text] [Related]  

  • 24. [Complications of drug therapy].
    Lebedeva GV; Kriukova OI; Zelenina OI; Gess LV; Alekseeva IA
    Vestn Dermatol Venerol; 1983 May; (5):44-7. PubMed ID: 6224363
    [No Abstract]   [Full Text] [Related]  

  • 25. Levonorgestrel-releasing intra-uterine systems (LNG-IUS) and breast cancer.
    Neven P; Amant F; Poppe W; Van den Broecke R
    Fertil Steril; 2009 Apr; 91(4):e5; author reply e6. PubMed ID: 19249759
    [No Abstract]   [Full Text] [Related]  

  • 26. Intolerance of fondaparinux in a patient allergic to heparins.
    Hirsch K; Ludwig RJ; Lindhoff-Last E; Kaufmann R; Boehncke WH
    Contact Dermatitis; 2004 Jun; 50(6):383-4. PubMed ID: 15274739
    [No Abstract]   [Full Text] [Related]  

  • 27. [Levonorgestrel-releasing intrauterine device (Mirena) and breast cancer: what do we learn from literature for clinical practice?].
    Boutet G
    Gynecol Obstet Fertil; 2006 Nov; 34(11):1015-23. PubMed ID: 17092752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immediate type hypersensitivity after injection of nadroparin (Fraxiparin).
    Bekkenk MW; van Zuuren EJ
    Thromb Haemost; 2005 Sep; 94(3):673-4. PubMed ID: 16268488
    [No Abstract]   [Full Text] [Related]  

  • 29. Hair loss with use of the levonorgestrel intrauterine device.
    Paterson H; Clifton J; Miller D; Ashton J; Harrison-Woolrych M
    Contraception; 2007 Oct; 76(4):306-9. PubMed ID: 17900442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A guide to understanding adverse drug reactions.
    Seal R
    Community Nurse; 2000 Apr; 6(3):53-6. PubMed ID: 12778510
    [No Abstract]   [Full Text] [Related]  

  • 31. [Ambulatory oral provocation testing].
    Wüthrich B
    Hautarzt; 1995 May; 46(5):352-3. PubMed ID: 7607902
    [No Abstract]   [Full Text] [Related]  

  • 32. Red and wet.
    van Westerloo DJ; Juffermans NP
    Neth J Med; 2010 May; 68(5):228-31. PubMed ID: 20508274
    [No Abstract]   [Full Text] [Related]  

  • 33. Autoimmune progesterone dermatitis.
    Chawla SV; Quirk C; Sondheimer SJ; James WD
    Arch Dermatol; 2009 Mar; 145(3):341-2. PubMed ID: 19289782
    [No Abstract]   [Full Text] [Related]  

  • 34. Autoimmune progesterone dermatitis mimicking fixed drug eruption.
    Salman A; Ergun T
    J Dtsch Dermatol Ges; 2017 Feb; 15(2):219-220. PubMed ID: 28084691
    [No Abstract]   [Full Text] [Related]  

  • 35. Levonorgestrel1--Leiras Oy. Levonova, Mirena.
    Drugs R D; 2002; 3(6):395-7. PubMed ID: 12516943
    [No Abstract]   [Full Text] [Related]  

  • 36. Rosacea in association with the progesterone-releasing intrauterine contraceptive device.
    Choudry K; Humphreys F; Menage J
    Clin Exp Dermatol; 2001 Jan; 26(1):102. PubMed ID: 11260192
    [No Abstract]   [Full Text] [Related]  

  • 37. [Minocycline hypersensibility syndrome].
    Gil P
    Ann Dermatol Venereol; 2000 Oct; 127(10):841-2. PubMed ID: 11060389
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC).
    van Vliet HA; Tchaikovski SN; Rosendaal FR; Rosing J; Helmerhorst FM
    Thromb Haemost; 2009 Apr; 101(4):691-5. PubMed ID: 19350113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of levonorgestrel-releasing intrauterine system on serum lipids and hepatic function].
    He SM
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1321-2, 1324. PubMed ID: 16234121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. von Willebrand's disease diagnosed after menorrhagia worsened from levonorgestrel intrauterine system.
    Lukes AS; Perry S; Ortel TL
    Obstet Gynecol; 2005 May; 105(5 Pt 2):1223-6. PubMed ID: 15863590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.